Perhaps BristolMS will still bid for vla. Their Nektar deal is...

Perhaps BristolMS will still bid for vla.

Their Nektar deal is amazing in the fact that they have paid US$1.85b upfront, nearly US$2b more in milestones, but will only get 35% of the drugs profits.

So they are paying masses, but this is for a drug that has been trialed with Opdivo or an Opdivo
/Yervoy combination.

Cavatax has done well with Yervoy alone.

If BMS are happy to pay over $4b Australian to get 35% of Nektar's drug, surely they won't mind going up as high as $1b for 100% of vla's.

Remember it's not only about improving their own drug, but stopping there biggest competitor in this space (Merck) improving theirs.

cheers